TGFB1 and Hepatic fibrosis: Although there have been many clinical reports focused on the importance of TGF-β activation in the pathogenesis of liver fibrosis in patients, its inhibition causes undesirable side effects, thereby decreasing the therapeutic advantages [15,17,18].